Kimberly-Clark Seeks EU Antitrust Clearance for Kenvue Deal
Kimberly-Clark has filed with European antitrust regulators to get its Kenvue deal reviewed, a key step before any merger can close.
If you've been watching the Kimberly-Clark and Kenvue saga, here's a notable development: Kimberly-Clark has formally filed with European antitrust authorities seeking regulatory clearance for its proposed deal with Kenvue. This kind of filing is standard procedure when two sizable companies want to combine — regulators in major markets like the EU get to weigh in before anything is finalized.
European antitrust review is no rubber stamp. The EU's competition watchdog takes a close look at whether a proposed deal could hurt consumers by reducing competition in any given market. For consumer goods giants like Kimberly-Clark — the company behind brands like Huggies and Kleenex — and Kenvue, which spun off from Johnson & Johnson and owns names like Neutrogena and Tylenol, regulators will want to make sure shoppers aren't left with fewer choices or higher prices on everyday products.
Read more Calian Group Selling US Commercial IT Unit to Trace3 →
Filing with the European regulator is one of several hurdles a deal like this typically needs to clear. Companies often have to seek approval in multiple jurisdictions simultaneously, meaning this EU filing is likely just one piece of a broader regulatory puzzle that could also involve US and other international authorities. Until all the necessary green lights are given, the deal remains in a holding pattern.
For everyday investors holding shares in either company, this filing signals the deal is moving through the required legal channels — but it's not a guarantee of approval. Antitrust reviews can take months, and regulators sometimes demand divestitures or other concessions before signing off. Keeping an eye on how European officials respond will be key to understanding the timeline here.
Continue reading at SeekingAlpha
